Plunkett Research Online: Akero Therapeutics Inc

AKERO THERAPEUTICS INC (AKRO:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Akero Therapeutics, Inc., together with its wholly-owned subsidiary Akero Securities Corporation, is a clinical-stage biotechnology company that develops and commercializes transformative treatments with serious metabolic diseases. The firm’s focus is on non-alcoholic steatohepatitis (NASH), a dise.....



Akero Therapeutics Inc
Ticker: AKRO
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 650 487-6488
Fax:
Address: 170 Harbor Way
3rd Floor
South San Francisco, CA 94080 United States

Types Of Business
Industry Ranks

Industry NAICS code:

Pharmaceutical Preparation Manufacturing
ContactsDescription

Andrew ChengCEO/Director/President
William WhiteCFO/Executive VP/Other Corporate Officer
See More
Akero Therapeutics, Inc., together with its wholly-owned subsidiary Akero Securities Corporation, is a clinical-stage biotechnology company that develops and commercializes transformative treatments with serious metabolic diseases. The firm’s focus is on non-alcoholic steatohepatitis (NASH), a dise.....See More See More

Auditor: Deloitte & Touche LLP
Legal Advisor:
$USD, In whole numbers,
except marked * or %
20192018
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and AffiliatesTop Salaries
Akero Securities Corporation
AKR-001
NameTitleSalary (US$)Bonus (US$)
Other ThoughtsCorporate Culture

Apparent Female Officers or Directors: